Endocrine late effects of cancer treatment

Current Opinion in Pediatrics

Volumn 15, Issue 1, 2003, Pages 3-9

  Cohen, Laurie E ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CALCITRIOL; CYTOTOXIC AGENT; GLUCOCORTICOID; GROWTH HORMONE; INTERLEUKIN 6; METHOTREXATE; PROTIRELIN; SOMATOMEDIN C; THYROTROPIN; VITAMIN D RECEPTOR;

ADRENAL INSUFFICIENCY; CANCER THERAPY; CHILDHOOD CANCER; DUAL ENERGY X RAY ABSORPTIOMETRY; ENDOCRINE DISEASE; GONADAL DISEASE; GROWTH HORMONE DEFICIENCY; HODGKIN DISEASE; HUMAN; HYPERPROLACTINEMIA; HYPERTHYROIDISM; HYPOGONADOTROPIC HYPOGONADISM; HYPOPHYSIS DISEASE; HYPOTHALAMUS DISEASE; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; HYPOTHALAMUS HYPOPHYSIS THYROID SYSTEM; HYPOTHYROIDISM; MOLECULAR MECHANICS; MULTIMODALITY CANCER THERAPY; OBESITY; OSTEOPENIA; OSTEOPOROSIS; OVARY INSUFFICIENCY; PRECOCIOUS PUBERTY; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIVITY; REFERENCE VALUE; REVIEW; SKULL IRRADIATION; TESTIS DISEASE; THYROID CANCER; THYROID DISEASE; THYROID NODULE;

AGE FACTORS; ANTINEOPLASTIC AGENTS; ENDOCRINE SYSTEM DISEASES; HUMANS; NEOPLASMS; RADIOTHERAPY; TIME FACTORS;

EID: 0037305942     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-200302000-00002     Document Type: Review

References (53)

1. Sklar CA: Endocrine complications of the successful treatment of neoplastic diseases in childhood. Growth Genet Horm 2001, 17:37-42. •• An excellent review, which provides more in-depth coverage of some of the subjects in this article for which there were not many current studies.
2. Sklar CA: Childhood brain tumors. J Pediatr Endocrinol 2002, 15(suppl 2):669-673.
3. Merchant TE, Williams T, Smith JM, et al.: Preirradiation endocrinopathies in pediatric brain tumor patients determined by dynamic tests of endocrine function. Int J Radiat Oncology Biol Phys 2002, 54:45-50. • This study suggests there is an overestimation in the incidence of radiation-induced endocrinopathies in other studies. However, abnormal test results may not necessarily define true pathology.
4. Lannering B, Albertsson Wikland K: Growth hormone release in children after cranial irradiation. Horm Res 1987, 27:13-22.
5. Constine LS, Woolf PD, Cann D, et al.: Hypothalamic-pituitary dysfunction after radiation for brain tumors. N Engl J Med 1993, 328:87-94.
6. Gleeson HK, Shalet SM: Endocrine complications of neoplastic diseases in children and adolescents. Curr Opin Pediatr 2001, 13:346-351.
7. Shalet SM: Radiation and pituitary dysfunction. N Engl J Med 1993, 328:131-133.
8. Brennan BMD, Shalet SM: Endocrine late effects after bone marrow transplant. Br J Haematol 2002, 118:58-66.
9. Holm K, Nyson K, Rasmussen MH, et al.: Growth, growth hormone, and final height after BMT. Possible recovery of irradiation-induced growth hormone insufficiency. Bone Marrow Transplant 1996, 18:163-170.
10. Brennan BMD, Rahim A, Mackie EM, et al.: Growth hormone status in adults treated for acute lymphoblastic leukemia in childhood. Clin Endocrinol 1998, 48:777-783.
11. Costin G: Effects of low-dose cranial radiation on growth hormone secretory dynamics and hypothalamic-pituitary function. Amer J Dis Child 1988, 142:847-852.
12. Stubberfield TG, Byrne GC, Jones TW: Growth and growth hormone secretion after treatment for acute lymphoblastic leukemia in childhood. 18-Gy versus 24-Gy cranial irradiation. J Pediatr Hematol Oncol 1995, 17:167-171.
13. Lannering B, Rosberg S, Marky I, et al.: Reduced growth hormone secretion with maintained periodicity following cranial irradiation in children with acute lymphoblastic leukemia. Clin Endocrinol 1995, 42:153-159.
14. Shalet SM, Price DA, Beardwell CG, et al.: Normal growth despite abnormalities of growth hormone secretion in children treated for acute leukemia. J Pediatr 1979, 94:719-722.
15. Hata M, Ogino I, Aida N, et al.: Prophylactic cranial irradiation of acute lymphoblastic leukemia in childhood: Outcomes of late effects on pituitary function and growth in long-term survivors. Int J Cancer (Radiat Oncol Invest) 2001, 96(suppl):117-124.
16. Adan L, Trivin C, Saint-Rose C, et al.: GH deficiency caused by cranial irradiation during childhood: Factors and markers in young adults. J Clin Endocrinol Metab 2001, 86:5245-5251. • This study shows that residual GH secretion and IGF-1 levels correlate with cranial RT doses to the hypothalamic-pituitary area. However, there is much overlap between groups.
17. Merchant TE, Goloubeva O, Pritchard DL, et al.: Radiation dose-volume effects on growth hormone secretion. Int J Radiat Oncol Biol Phys 2002, 52:1264-1270. • This study showed peak GH responses depend on hypothalamic dose-volume effects. However, the relation between peak GH responses and GH deficiency is not clear out.
18. Littley MD, Shalet SM, Beardwell CG, et al. Radiation-induced hypopituitarism is dose-dependent. Clin Endocrinol 1989, 31:363-373.
19. Schmiegelow M, Lassen S, Poulsen HS, et al.: Gonadal status in male survivors following childhood brain tumors. J Clin Endocrinol Metab 2001, 86:2446-2452.
20. Lando A, Holm K, Nyson K, et al.: Thyroid function in survivors of childhood acute lymphoblastic leukaemia: The significance of prophylactic cranial irradiation. Clin Endocrinol 2001, 55:21-55.
21. Livesey EA, Hindmarsh PC, Brook CGD, et al.: Endocrine disorders following treatment of childhood brain tumors. Br J Cancer 1990, 61:622-625.
22. Rose SR, Lustig RH, Pitukcheewanont P, et al.: Diagnosis of hidden central hypothyroidism in survivors of childhood cancer. J Clin Endocrinol Metab 1999, 84:4472-4479.
23. Oelkers W: Adrenal insufficiency. N Engl J Med 1996, 335:1206-1212.
24. Felner EI, Rhompson MT, Ratliff AF, et al.: Time course of recovery of adrenal function in children treated for leukemia. J Pediatr 2000, 137:21-24.
25. Kuperman H, Damiani D, Chrousos GP, et al.: Evaluation of the hypothalamic-pituitary adrenal axis in children with leukemia before and after 6 weeks of high-dose glucocorticoid therapy. J Clin Endocrinol Metab 2001, 86:2993-2996. • This study showed that up to 2 weeks after discontinuation of 6 weeks of high-dose dexamethasone administration, the hypothalamic-pituitary-adrenal axis is mildly suppressed. The stress of the disease and the chemotherapy and/or concurrent infectious processes may protect this axis to some extent.
26. Chemaitilly W, Trivin C, Adan L, et al.: Central precocious puberty: clinical and laboratory features. Clin Endocrinol 2001, 54:289-294.
27. Cheng WY, Chang CS, Shen CC, et al.: Endoscope-assisted microsurgery for treatment of a suprasellar craniopharyngioma presenting precocious puberty. Pediatr Neurosurg 2001, 34:247-251.
28. Rivarola MA, Belgorosky A, Mendilaharzu H, et al.: Precocious puberty in children with tumors of the suprasellar and pineal areas: organic central precocious puberty. Acta Paediatr 2001, 90:751-756.
29. Ogilvy-Stuary AL, Clayton PE, Shalet SM: Cranial irradiation and early puberty. J Clin Endocrinol Metab 1994, 78:1282-1286.
30. Paulino RC: Hypothyroidism in children with medulloblastoma: a comparison of 3600 and 2340 cGy craniospinal radiotherapy. Int J Radiat Oncol Biol Phys 2002, 53:543-547. • In spite of RT dose being directly related to the development of endocrinopathies, this study showed that current treatment regimens for medulloblastoma consisting of chemotherapy and low-dose craniospinal irradiation of 2340 cGy do not show a reduction of hypothyroidism compared with standard-dose craniospinal irradiation of 3600 cGy. This study supports young age and use of chemotherapy being associated with a higher incidence of hypothyroidism (prior data on both of these parameters are conflicted).
31. Ricardi U, Corrias A, Einaudi S, et al.: Thyroid dysfunction as a late effect in childhood medulloblastoma: A comparison of hyperfractionated versus conventionally fractionated craniospinal radiotherapy. Int J Radiat Oncol Biol Phys 2001, 50:1287-1294. •• This study suggests hyperfractionated RT may preserve some thyroid function, although follow-up time in the hyperfractionated group was less than in the conventional group.
32. Sutcliffe SB, Chapman R, Wrigley PFM: Cyclical combination chemotherapy and thyroid function in patients with advanced Hodgkin's disease. Med Pediatr Oncol 1981, 9:439-448.
33. Socie G, Curtis RE, Deeg HJ, et al.: New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol 2000, 18:348-357.
34. Kenney LB, Laufer MB, Grant FD, et al.: High risk of infertility and long term gonadal damage in males treated with high dose cyclophosphamide for sarcoma during childhood. Cancer 2001, 91:613-621.
35. Rueffer U, Breuer K, Josting A, et al.: Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment. Ann Oncol 2001, 12:1307-1311. • This study showed a high rate of infertility prior to treatment in Hodgkin disease, suggesting that treatment effects may be overestimated.
36. Sklar C: Reproductive physiology and treatment-related loss of sex hormone production. Med Pediatr Oncol 1999, 33:2-8.
37. Byrne J, Fears TR, Gail MH, et al.: Early menopause in long-term survivors of cancer during adolescence. Am J Obstet Gynecol 1992, 166:788-793.
38. Tauchmanova L, Selleri C, de Rosa G, et al.: High prevalence of endocrine dysfunction in long-term survivors after allogeneic bone marrow transplantation for hematologic diseases. Cancer 2002, 95:1076-1084.
39. Couto-Silva AC, Trivin C, Thibaud E, et al.: Factors affecting gonadal function after bone marrow transplantation during childhood. Bone Marrow Transplant 2001, 28:67-75.
40. Haddy TB, Mosher RB, Reaman GH: Osteoporosis in survivors of acute lymphoblastic leukemia. Oncologist 2001, 6:278-285.
41. Tillmann V, Darlington AS, Eiser C, et al.: Male sex and low physical activity are associated with reduced spine bone mineral density in survivors of childhood lymphoblastic leukemia. J Bone Miner Res 2002, 17:1073-1080. • A small but well-designed study that controlled for physical activity, body composition, and calcium intake.
42. Kaste SC, Jones-Wallace D, Rose SR, et al.: Bone mineral decrements in survivors of childhood acute lymphoblastic leukemia: Frequency of occurrence and risk factors for their development. Leukemia 2001, 15:728-734.
43. Lequin MH, van der Shuis IM, van Rijn RR, et al.: Bone mineral assessment with tibial uitrasonometry and dual-energy X-ray absorptiometry in long-term survivors of acute lymphoblastic leukemia in childhood. J Clin Densitom 2002, 5:167-173.
44. Nysom K, Holm K, Michaelsen KF, et al.: Bone mass after treatment of malignant lymphoma in childhood. Med Pediatr Oncol 2001, 37:518-524. • Most studies of BMD are in ALL survivors; in this study, survivors of malignant lymphoma were evaluated.
45. Lee WY, Kang MI, Oh ES, et al.: The role of cytokines in the changes in bone turnover following bone marrow transplantation. Osteoporosis Int 2002, 13:62-68. This study prospectively assessed the relationship between bone turnover markers and cytokines in BMT recipients.
46. Lee WY, Cho SW, Oh ES, et al.: The effect of bone marrow transplantation on the osteoblastic differentiation of human bone marrow stromal cells. J Clin Endocrinol Metab 2002, 87:329-335. •• The first study to look at differentiation of bone marrow stromal cells into osteoblasts using ex vivo bone marrow stromal cell cultures in the BMT setting.
47. Banfey A, Podesta M, Fazzuoli L, et al.: High-dose chemotherapy shows a dose-dependent toxicity to bone marrow osteoprogenitors. A mechanism for post-bone marrow transplant osteopenia. Cancer 2001, 92:2419-2428. • A study that used bone turnover markers to look at decreased BMD after BMT.
48. Lustig RH: Hypothalamic obesity: the sixth cranial endocrinopathy. Endocrinologist 2002, 12:210-217. •• An excellent review of a previously unrecognized endocrinopathy. This article focuses on VMH destruction leading to a vagally mediated potentiation of insulin secretion in response to glucose.
49. Pinkney J, Wilding J, Williams G, et al.: Hypothalamic obesity in humans: what do we know and what can be done? Obes Rev 2002, 3:27-34. • A nice overview of hypothalamic obesity, but not in depth.
50. Muller HL, Bueb K, Bartels U, et al.: Obesity after childhood craniopharyngioma-German multicenter study on preoperative risk factors and quality of life. Klin Padiatr 2001, 213:244-249. •• A retrospective study that identified pretreatment risk factors for the development of obesity in patients with craniopharyngiomas, including familial disposition for obesity.
51. Merchant TE, Kiehna EN, Sanford RA, et al.: Craniopharyngioma: The St. Jude Children's Research Hospital Experience 1984-2001. Int J Radiat Oncol Biol Phys 2002, 53:533-542. • A retrospective study that showed that limited surgery and radiotherapy cause lesser or comparable sequelae in patients with craniopharyngiomas.
52. Warner JT, Evans WD, Webb DKH, et al.: Body composition of long-term survivors of acute lymphoblastic leukemia. Med Pediatr Oncol 2002, 38:165-172. •• This study showed an increased amount of body fat in female survivors of ALL and suggests that published equations for BMI underestimate body fat measurements and should be used with caution.
53. Reilly JJ, Brougham M, Montgomery C, et al.: Effect of glucocorticoid therapy on energy intake in children treated for acute lymphoblastic leukemia. J Clin Endocrinol Metab 2001, 86:3742-3745. • This study quantitated the effects of dexamethasone and prednisone on energy intake in children treated for ALL.